BC Extra | Oct 7, 2019
Company News

Amid management shakeup, Akcea strikes latest antisense deal

Akcea will bank $250 million up front from a new licensing deal with Pfizer, adding to a balance sheet already fattened by a February deal with Novartis for another antisense oligonucleotide program based on Akcea's...
BioCentury | Sep 7, 2019
Product Development

Regeneron’s evinacumab data could make it the therapy of choice in HoFH

With a cleaner safety profile and better efficacy than marketed agents, Regeneron’s first-in-class evinacumab is poised to become the standard of care for homozygous familial hypercholesterolemia and other rare lipid disorders, including for the hardest...
BC Extra | Aug 14, 2019
Clinical News

Regeneron data could set up first-in-class approval in lipid-lowering indication

Regeneron's evinacumab could give certain hypercholesterolemia patients a new treatment option, with an FDA submission looming based on new results from a Phase III trial evaluating the first-in-class therapy as an add-on to existing treatments....
BC Week In Review | Jul 14, 2017
Clinical News

Regeneron reports Phase II data for evinacumab in HoFH

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from an open-label, international Phase II trial in 9 patients with homozygous familial hypercholesterolemia (HoFH) showing that evinacumab (REGN1500) added to current lipid-lowering therapy reduced mean LDL-C from baseline...
BC Week In Review | May 12, 2017
Clinical News

FDA grants Regeneron's evinacumab breakthrough therapy designation for HoFH

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA granted breakthrough therapy designation to evinacumab (REGN1500) to treat homozygous familial hypercholesterolemia (HoFH). The mAb targeting angiopoietin-like 3 (ANGPTL3) is in Phase II testing for the indication. Regeneron Pharmaceuticals...
BC Innovations | Jan 26, 2017

Deep roots

Regeneron Pharmaceuticals Inc . is starting to see the fruits of its experiment with Geisinger Health System to mine vast quantities of patient data for links between genotype and phenotype. Three years into the project, the...
BioCentury | Jun 15, 2015

LDL in context

Discussion at last week's advisory committee meeting for the PCSK9 inhibitors Repatha evolocumab and Praluent alirocumab suggest that, for first-in-class hypercholesterolemia candidates, the agency and the committee are leaning toward narrowing the use of LDL...
BC Extra | Nov 5, 2014
Top Story

Eylea numbers surprise Street

Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) fell $22.87 to $372.39 on Tuesday after it lowered the top end of its guidance for U.S. sales of Eylea aflibercept in 2014 and cautioned that the sales ramp...
Items per page:
1 - 8 of 8